Barclays analyst Etzer Darout lowered the firm’s price target on AnaptysBio (ANAB) to $55 from $70 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB: